LIFE SCIENCE TREND ANALYSIS

NETHERLANDS | 2024





hollandbio



ABOUT US



The following statistical information has been obtained from **Biotechgate**, a global, comprehensive life science database encompassing the biotechnology, pharmaceutical and medical device industries.

www.biotechgate.com



The Dutch Life Sciences Database is a part of the global Biotechgate and is brought to you in partnership with **hollandbio**.

www.dutchlifescience.com



Biotechgate is owned and operated by **Venture Valuation AG**, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the life sciences (biotech, pharma, medtech), ICT, high-tech, nanotech, cleantech and renewable energy.

www.venturevaluation.com

OUR PARTNER

hollandbio

Hollandbio connects, supports, and represents over 280 medical, agro-food, and industrial biotech companies. Their members are active in all phases of research and development and include all company sizes: start-ups, SMEs, listed companies and multinationals.


Together, they strive for a society taking full advantage of the power of biotechnology in health, food and sustainability.

Explore the hollandbio life Science Database run by Biotechgate, which shows the Netherland's vibrant, dense biotechnology cluster of over 2000 life sciences companies and research organizations, all within a 120-mile radius.

OVERVIEW OF THE LIFE SCIENCE INDUSTRY

NUMBER OF COMPANIES BY SECTOR










OVERVIEW OF BIOTECH COMPANIES

NUMBER OF COMPANIES BY SECTOR



• BIOTECH • **THERAPEUTICS** 180


BIOTECH COMPANIES 556 • BIOTECH • R&D SERVICES
229

• BIOTECH • OTHER
147



BIOTECH - THERAPEUTICS & DIAGNOSTICS COMPANIES BY KEY ACTIVITIES

AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - THERAPEUTICS COMPANIES




For **180** Biotech Therapeutics companies there were **302** subsectors (key activity areas) assigned (one biotech company can be active in multiple areas). The graph displays Biotech – Therapeutics and Diagnostics subsectors as the percentage of the total number of Biotech – Therapeutics and Diagnostics subsectors with exclusion of the category "Others" or categories with a share of 2% or less. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Information displayed may alter as new information is received continuously.



BIOTECH - OTHER COMPANIES BY KEY ACTIVITIES

AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - OTHER COMPANIES



For **147** Biotech - Other companies there were **218** subsectors (key activity areas) assigned (one biotech company can be active in multiple areas). The graph displays Biotech – Other subsectors as the percentage of the total number of Biotech – Other subsectors with exclusion of the category Others. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Information displayed may alter as new information is received continuously.






BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BY INDICATION AND DEVELOPMENT PHASE


BREAKDOWN BY INDICATION

BREAKDOWN BY DEVELOPMENT PHASE




Both graphs contain the number of assets of Biotech - Therapeutics and Diagnostics companies (excl. Pharma or Biotech - Others or Biotech R&D Services

II/III trials are merged into Phase III category. Information displayed in the chart may alter as new information is received continuously.



ASSETS AVAILABLE FOR OUT-LICENSING


NUMBER OF ASSETS





OVERVIEW OF OWNERSHIP

PERCENTAGE OF TOTAL NUMBER OF COMPANIES BY OWNERSHIP AND SECTOR



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Biotech T&D stands for Biotech Therapeutics and Diagnostics. Percentage value is expressed as % of total number of companies in the sector. Information displayed may alter as new


information is received continuously.





COMPANY FOUNDATION TIMELINE

NUMBER OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR | 2013-2022



The graph contains the number of privately owned or publicly listed (no subsidiaries) life science companies founded by year including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. Companies founded in 2023 were excluded since newly founded companies often remain under the radar until their first financing round. Information displayed in the chart may alter as new information is received continuously.



VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS | 2022-2023

LIFE SCIENCE COMPANIES




BIOTECH COMPANIES





BIOTECH VENTURE FINANCING

PRIVATE EQUITY ROUNDS - 5 YEAR REPORT





BIOTECH IPOs

DUTCH BIOTECH COMPANIES THAT WENT PUBLIC WORLDWIDE | 2014-2023



MAJOR BIOTECH VENTURE FINANCING ROUNDS (2023)

TOP 5 DUTCH PRIVATE EQUITY FINANCING ROUNDS | 2023

Company		Sector	Type of Round	USD M
VectorY Therapeutics	VectorY THERAPEUTICS	Biotech – Therapeutics	Series A	\$137
Tagworks Pharmaceutcials BV	TAGWORKS	Biotech – Therapeutics	Series A	\$65
KyNexis B.V.	Kynexis	Biotech - Therapeutics	Series A	\$57
Meatable B.V.	M. M.	Biotech – Other	Series B	\$35
VarmX B.V.	VarmX	Biotech – Therapeutics	Series B	\$33

MAJOR BIOTECH AND PHARMA M&A DEALS (2023)

TOP 5 M&A DEALS | 2023

Acquired	d entity	Buyer		Phase of lead asset (of acquired entity)	USD M
Neogene Therapeutics	, Inc. neogene	AstraZeneca PLC	AstraZeneca	Phase I	\$320
Adare Biome	ADARE BIOME	Koninklijke DSM N.V.	DSM	On the market	\$299
Xinvento BV	XINVENTO	Rhythm Pharmaceuticals Netherlands B.V.	Rhythm	N/A	\$211
Synaffix BV	Synaffix	Lonza Group Ltd	Lonza	N/A	\$172
Verogen, Inc.	VEROGEN	Qiagen NV	QIAGEN	N/A	\$150

BENCHMARK REPORT

NETHERLANDS | FRANCE | GERMANY | UNITED KINGDOM | DENMARK | SWITZERLAND | USA









OVERVIEW OF LIFE SCIENCE COMPANIES

LIFE SCIENCE AND BIOTECH COMPANIES BY COUNTRY AND SECTOR




OVERVIEW OF LIFE SCIENCE COMPANIES

LIFE SCIENCE COMPANIES BY COUNTRY AND SECTOR




OVERVIEW OF BIOTECH COMPANIES

BIOTECH COMPANIES BY COUNTRY AND SECTOR



BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BREAKDOWN BY TOP THREE INDICATIONS OF NETHERLANDS




The graph contains the rate of assets of Biotech – Therapeutics and Diagnostics companies per million residents of each country (excl. of Pharma or Biotech – Others or Biotech – R&D Services companies). The top three indications of the Netherlands shown are Oncology, Infectiology/parasitology, and Neurology.





THERAPEUTICS BY DEVELOPMENT PHASE

PRECLINICAL AND PHASE I








COMPANY FOUNDATION TIMELINE

RATE OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR PER MILLION RESIDENTS | 2013-2022




The graph contains the rate of privately owned or publicly listed (no subsidiaries) life science companies founded by year per million residents of each country, including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech – Others, Pharma, Medical Technology and Digital Health companies.

Companies founded in 2023 were excluded since newly founded companies often remain under the radar until their first financing round. Information displayed in the chart may alter as new information is received continuously.




VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS OF LIFE SCIENCE COMPANIES (EUROPE AND USA) | 2022-2023



BIOTECH COMPANIES





VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS OF LIFE SCIENCE COMPANIES | 2022-2023

companies. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously

received and/or new tranches to existing financing rounds are added. The graph shows the benchmark countries excl. the United States.







VENTURE FINANCING OF BIOTECH COMPANIES

PRIVATE EQUITY ROUNDS OF BIOTECH COMPANIES | 2022-2023







MAJOR BIOTECH VENTURE FINANCING ROUNDS (2023)

TOP PRIVATE EQUITY FINANCING ROUNDS | 2023

Company	Type of Round	USD M	Country	
Apollo Therapeutics	Series C	\$227	United Kingdom	
Amolyt Pharma SAS	Series C	\$138	France	
VectorY Therapeutics	Series A	\$137	Netherlands	
Hemab Therapeutics	Series B	\$135	Denmark	
Noema Pharma AG	Series B	\$110	Switzerland	
Alentis Therapeutics AG	Series C	\$105	Switzerland	
NMD Pharma A/S	Series B	\$80	Denmark	
Complement Therapeutics Ltd	Series A	\$78	United Kingdom	
Corteria Pharmaceuticals	Series A	\$76	France	
Nouscom AG	Series C	\$72	Switzerland	

ABOUT BIOTECHGATE



Biotechgate is a leading **business development and licensing database** for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 44,000 **licensing deals** and a **clinical trials database** containing over 850,000 records from registries around the world.

To register for a free trial access or to learn more about the different subscription options, please visit www.biotechgate.com.

TERMS OF USE

The Life Sciences Trend Analysis is based on data entered in the Biotechgate Database available at www.biotechgate.com. The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The use of the figures and graphs provided in this report is free of charge for any presentations as long as www.biotechgate.com is clearly cited as the source. For all other uses please contact us for terms and conditions.



BIOTECHGATE

c/o Venture Valuation VV AG

Kasernenstrasse 11

8004 Zurich

SWITZERLAND



+41 (43) 321 86 60



www.venturevaluation.com